By Budi Oetomo Narendra 
Researchers at Baylor College of Medicine have developed an experimental drug, CS18, which demonstrates significant potential in re-sensitizing tumors that have become resistant to conventional cancer therapies. The groundbreaking study, recently published in the esteemed journal Science Advances, offers compelling early evidence that supports the continued investigation of CS18 as a novel therapeutic agent, potentially reshaping future strategies for managing advanced cancers. This development addresses one of the most formidable challenges in oncology: the ability of cancer cells to evolve and evade the cytotoxic effects of otherwise effective treatments, leading to patient relapse and poorer outcomes.
The Pervasive Challenge of Therapeutic Resistance
Cancer remains a leading cause of morbidity and mortality globally, with millions of new diagnoses each year. While advancements in surgical techniques, chemotherapy, radiation therapy, targeted agents, and immunotherapies have dramatically improved patient survival rates for many cancer types, the emergence of therapeutic resistance continues to be a primary obstacle to achieving durable remissions. Dr. Weei-Chin Lin, a corresponding author on the study and a distinguished professor of medicine in hematology and oncology, as well as molecular and cellular biology at Baylor College of Medicine, underscores this critical issue. "Therapeutic resistance is a main obstacle to achieve effective and durable cancer treatments," Dr. Lin stated. He elaborated that even when initial treatments are highly effective, a significant number of patients eventually experience a relapse. This recurrence often stems from cancer cells’ remarkable capacity to activate compensatory and convergent biological pathways. These cellular reprogramming events allow them to bypass the intended toxic effects of therapy, ultimately promoting their survival and continued proliferation.
The mechanisms of resistance are multifaceted and complex, ranging from genetic mutations that alter drug targets to epigenetic modifications that change gene expression, and the activation of alternative signaling pathways that bypass the inhibited one. For instance, targeted therapies designed to block specific proteins often face resistance through secondary mutations in the target protein itself or through the upregulation of parallel survival pathways. Immunotherapies, while revolutionary, can also encounter resistance as tumors learn to evade immune recognition or suppress immune cell activity. The relentless evolutionary pressure exerted by therapy often selects for resistant clones within a heterogeneous tumor population, leading to a more aggressive, treatment-refractory disease. This urgent unmet medical need drives the ongoing quest for new therapeutic strategies that can either prevent resistance from emerging or overcome it once established.
Targeting Cancer’s Central Survival Network: TopBP1-BRCT7/8
Rather than pursuing the conventional approach of targeting a single, isolated cancer pathway, which often leads to the rapid development of resistance, the Baylor research team embarked on developing a drug that could disrupt a broader, more fundamental control center involved in multiple cancer-promoting processes simultaneously. Their chosen target was topoisomerase IIβ-binding protein 1 (TopBP1), a protein the researchers ingeniously described as a ‘biological switchboard.’ TopBP1 plays a crucial role in regulating a multitude of pathways essential for cancer growth, DNA repair, and cell survival. Its involvement in such a wide array of cellular functions makes it an attractive, yet challenging, target for therapeutic intervention.
TopBP1 is a large scaffolding protein known for its multiple BRCT (BRCA1 C-terminal) domains, which are protein interaction modules. These domains are critical for TopBP1’s function in orchestrating DNA damage response, DNA replication, and cell cycle checkpoints. By acting as a central hub, TopBP1 can integrate signals from various cellular stress pathways and relay them to downstream effectors, thus controlling cell fate decisions, including proliferation or apoptosis (programmed cell death). The researchers hypothesized that by disrupting this central control point, they could achieve more profound and longer-lasting treatment responses, effectively overcoming the sophisticated resistance mechanisms employed by cancer cells.
Within the intricate architecture of TopBP1, the research team specifically focused on the BRCT7/8 switch. Dr. Lin elaborated on the rationale for this particular focus: "Of all the ‘biological switches’ on TopBP1, switch BRCT7/8 interacts with several key regulators of cancer growth, including MIZ1, a suppressor of cancer driver MYC; mutant p53, which can acquire cancer-promoting functions; and PLK1 and CIP2A, proteins that help cancer cells survive and divide." This detailed understanding highlights the strategic importance of BRCT7/8. MIZ1 (MYC-interacting zinc finger protein 1) is involved in both MYC-dependent and MYC-independent transcriptional regulation, often suppressing MYC’s oncogenic activity. MYC, a well-known oncogene, drives cell proliferation and growth, and its dysregulation is a hallmark of many cancers. Mutant p53 is another critical player; while wild-type p53 acts as a tumor suppressor, its mutated forms can lose this function and even gain new oncogenic properties, promoting tumor progression and resistance to therapy. PLK1 (Polo-like kinase 1) is a key regulator of cell cycle progression and is frequently overexpressed in various cancers, promoting uncontrolled division. CIP2A (Cancerous Inhibitor of Protein Phosphatase 2A) is an oncogenic protein that stabilizes MYC and promotes cell survival. "All together, these diverse roles position TopBP1-BRCT7/8 as a promising target for intervention," Dr. Lin concluded, emphasizing the potential for a single intervention to disrupt multiple critical cancer pathways simultaneously.
The Development of CS18: From Screening to Optimization
The journey to identify a compound capable of selectively blocking the TopBP1-BRCT7/8 interaction was a meticulous and multi-step process, combining advanced computational methods with rigorous laboratory experimentation. The researchers initiated a high-throughput screening campaign, evaluating thousands of chemical compounds for their ability to bind to and inhibit the BRCT7/8 domain. This complex undertaking involved sophisticated computer modeling techniques, which allowed the team to virtually screen large libraries of molecules and predict their binding affinities and interactions with the target protein. Such in silico methods significantly accelerate the drug discovery process by narrowing down the vast chemical space to a manageable number of promising candidates.
Following the computational predictions, the most promising compounds were subjected to extensive laboratory experiments. This combined approach led to the identification of an initial lead compound, designated as 3B6. While 3B6 showed some efficacy, it was not potent or selective enough for therapeutic development. Recognizing the potential of this initial hit, the team embarked on a chemical optimization program. This involved systematically modifying the molecular structure of 3B6, synthesizing numerous derivatives, and testing each version for improved potency, selectivity, and pharmacokinetic properties. This iterative process of synthesis and testing is a cornerstone of medicinal chemistry, aiming to refine a compound’s characteristics to maximize its therapeutic benefit while minimizing off-target effects. Through this rigorous optimization, the researchers eventually identified CS18 as the most effective candidate, exhibiting superior binding to BRCT7/8 and desirable pharmacological attributes.
The Multifaceted Mechanism of Action of CS18
The efficacy of CS18 stems from its ability to disrupt the critical interactions mediated by the BRCT7/8 domain, leading to a cascade of anti-cancer effects within the cell. Dr. Lin elucidated the key mechanisms: "When CS18 binds to BRCT7/8, the cancer-promoting activities of MYC and mutant p53 decreased, proteins involved in DNA repair became less active and cancer cells were more likely to die." This is a profound statement, as it signifies CS18’s capacity to simultaneously tackle multiple oncogenic drivers. By reducing the activity of MYC, CS18 can curb the uncontrolled proliferation that characterizes cancer. Similarly, by attenuating the cancer-promoting functions of mutant p53, it addresses a major mechanism of tumor progression and therapeutic resistance.
Furthermore, the impairment of DNA repair mechanisms is a particularly important aspect of CS18’s action. Cancer cells often exhibit heightened DNA damage response pathways, which enable them to survive the genotoxic stress induced by chemotherapy and radiation. By making proteins involved in DNA repair less active, CS18 effectively renders cancer cells more vulnerable to DNA damage, potentially enhancing the efficacy of other treatments that work by inducing such damage. This dual action – directly inhibiting oncogenic pathways and sensitizing cells to DNA damage – creates a powerful anti-cancer synergy. "In addition, CS18 increased the activity of genes that stop uncontrolled cancer growth," Dr. Lin added. This suggests that CS18 not only disrupts pro-survival signals but also actively promotes tumor suppressive pathways, pushing cancer cells towards a state of senescence or apoptosis. "Altogether, CS18 appears to reduce several of the defenses that help cancer cells survive therapy," he concluded, highlighting the drug’s comprehensive approach to dismantling cancer’s survival toolkit.
Preclinical Validation Across Multiple Cancer Types
The promise of CS18 was further substantiated through extensive preclinical testing across a diverse panel of cancer cell lines and in vivo animal models. The researchers observed the beneficial effects of CS18 across several aggressive and challenging cancer types, including triple-negative breast cancer (TNBC), ovarian cancer, lung adenocarcinoma, lung squamous cell carcinoma, and acute myeloid leukemia (AML). The broad spectrum of activity is particularly encouraging, suggesting that the underlying mechanisms targeted by CS18 (TopBP1-BRCT7/8) are fundamental to the survival and proliferation of a wide range of malignancies. TNBC, for instance, is notoriously difficult to treat due to its aggressive nature and lack of targeted therapeutic options. Ovarian cancer often presents at an advanced stage and frequently develops resistance to platinum-based chemotherapies. Lung cancers and AML also represent significant clinical challenges where novel therapeutic strategies are desperately needed.
Crucially, the studies also demonstrated that CS18 exhibited lower toxicity to non-cancerous cells, a critical parameter for any potential therapeutic agent. Selective toxicity towards cancer cells, while sparing healthy tissues, is a hallmark of an effective and tolerable anti-cancer drug, minimizing debilitating side effects for patients.
The results became particularly significant when CS18 was evaluated in combination with existing cancer drugs. This strategy of combination therapy is a cornerstone of modern oncology, aiming to achieve synergistic effects, overcome resistance, and reduce drug dosages. Combining CS18 with treatments such as PARP inhibitors or osimertinib resulted in more effective killing of cancer cells than either treatment used as a monotherapy. PARP inhibitors (e.g., olaparib, niraparib) are a class of targeted drugs used primarily in ovarian, breast, and prostate cancers with BRCA mutations, by exploiting deficiencies in DNA repair. Osimertinib is a third-generation EGFR tyrosine kinase inhibitor (TKI) widely used for non-small cell lung cancer (NSCLC) with EGFR mutations, particularly those that have developed resistance to earlier TKIs.
The ability of CS18 to enhance the efficacy of these established agents is a major finding. Dr. Lin specifically highlighted its impact on resistant lung cancer cells: "In the case of lung cancer cells that were already resistant to osimertinib, adding CS18 restored the cells’ sensitivity to osimertinib, increasing cancer cell death." This re-sensitization capability is profoundly important. Osimertinib resistance is a significant clinical problem, often leading to limited treatment options for patients. The ability of CS18 to circumvent this acquired resistance could offer a lifeline to patients whose tumors have become refractory to standard-of-care therapies. Beyond cell culture studies, the efficacy of CS18 was further confirmed in in vivo animal models. The researchers observed a significant reduction of tumor growth in these models, importantly, with "no major weight loss or other signs of toxicity." This favorable safety profile in preclinical models is a strong indicator of CS18’s potential for clinical translation.
A Potential New Strategy Against Drug Resistance and Future Implications
Based on these compelling preclinical findings, the researchers at Baylor College of Medicine strongly advocate for the further development of CS18 as a potential component of future combination cancer therapies. The implications of such a drug are far-reaching. CS18 could potentially serve a dual role: first, in preventing resistance from emerging when administered alongside initial treatments, thereby prolonging treatment efficacy and improving long-term patient outcomes. Second, and perhaps more immediately impactful, it could make resistant cancers responsive to therapy again, offering new hope to patients for whom current treatments have failed.
The journey from an experimental drug to a clinically approved therapy is arduous and lengthy, typically spanning a decade or more and costing billions of dollars. The next critical steps for CS18 involve further rigorous preclinical validation, including detailed toxicology studies and pharmacokinetic profiling, to support an Investigational New Drug (IND) application to regulatory bodies like the U.S. Food and Drug Administration (FDA). If approved, CS18 would then proceed to Phase 1 clinical trials in human volunteers, primarily focusing on safety and dose escalation, followed by Phase 2 trials to assess efficacy in specific cancer types, and ultimately Phase 3 trials for large-scale comparative effectiveness.
The development of CS18 represents a significant paradigm shift in oncology research, moving towards strategies that target the core survival mechanisms of cancer cells rather than isolated pathways. This multi-pronged approach holds promise for overcoming the inherent adaptability of cancer. Should CS18 prove safe and effective in human trials, it could be integrated into existing treatment protocols, potentially transforming the landscape for patients with drug-resistant malignancies. Leading oncologists often emphasize the critical need for such innovative approaches, acknowledging that incremental improvements are no longer sufficient to tackle the complex problem of cancer resistance. An independent expert in targeted therapy research, not directly involved in the study, might comment on the importance of targeting ‘switchboard’ proteins like TopBP1. "The beauty of targeting a central hub like TopBP1 is its potential to simultaneously dismantle multiple compensatory pathways that tumors exploit for survival," an expert might observe. "This type of approach is exactly what we need to stay ahead of cancer’s evolutionary game and provide more durable responses for patients."
This important work was made possible through the collaborative efforts of a dedicated research team. Other significant contributors to this work from Baylor College of Medicine included Fang-Tsyr Lin, Kang Liu, Yang Xiao, Lidija A. Wilhelms Garan, and Helena Folly-Kossi. Further collaboration extended to Shwu-Jiuan Lin at Taipei Medical University, underscoring the international nature of cutting-edge scientific research.
The project received substantial financial support from a variety of prestigious organizations, highlighting the critical role of funding in scientific discovery. Key grants were provided by the National Institutes of Health (NIH) under grant numbers R01CA203824, R01CA269971, T32CA174647, and T32GM136560. Additional support came from the Department of Defense (DoD) through grants W81XWH-18-1-0329, W81XWH-19-1-0369, W81XWH-22-1-0226, W81XWH-22-1-0534, and HT9425-24-1-0045. Further crucial funding was provided by a Rivkin Center for Ovarian Cancer Pilot Award and a Taiwan Ministry of Science and Technology grant (MOST 107-2635-B-038-001). These diverse funding sources exemplify the widespread recognition of the significance and potential impact of this research in the ongoing fight against cancer. While still in its early stages, CS18 represents a beacon of hope, demonstrating a novel pathway to circumvent therapeutic resistance and potentially improve the lives of countless cancer patients worldwide.
